Vaccine companies Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) and LimmaTech Biologics AG announced on Thursday a strategic partnership and licensing agreement for the development, manufacturing and commercialisation of Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis.
Under the agreement Valneva has acquired an exclusive global licence for S4V.
The deal includes an upfront payment of EUR10m to LimmaTech as well as potential regulatory, development and sales-based milestone payments and low double-digit royalties on sales.
Shigellosis, a diarrhoeal disease caused by Shigella bacteria, affects millions worldwide, particularly children in developing countries. Currently, no approved Shigella vaccine exists.
Valneva will now lead the vaccine's development, including Phase 2 clinical trials, while LimmaTech will continue to be involved in the Phase 2 studies. The global market for a Shigella vaccine is estimated at over USD500m annually.
MicuRx completes Phase III trial for MRX-4 for injection in China
Renalys Pharma secures Orphan Drug Designation in Japan for sparsentan
Minghui Pharmaceutical reports phase III success for MH004 ointment in atopic dermatitis
CBC Group acquires UCB's mature neurology and allergy business in China
MGI Tech collaborates with Universidad de San Martin de Porres
Allink Biotherapeutics completes USD42m Series A financing round
Galderma reports Phase III data for nemolizumab in prurigo nodularis published in JAMA Dermatology
Sichuan Kelun-Biotech's sacituzumab tirumotecan receives Chinese regulatory approval
Allergy Therapeutics begins Phase III trial for grass allergy treatment in children